全文获取类型
收费全文 | 872篇 |
免费 | 176篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 23篇 |
妇产科学 | 3篇 |
基础医学 | 167篇 |
口腔科学 | 15篇 |
临床医学 | 78篇 |
内科学 | 133篇 |
皮肤病学 | 6篇 |
神经病学 | 44篇 |
特种医学 | 194篇 |
外科学 | 82篇 |
综合类 | 78篇 |
预防医学 | 122篇 |
眼科学 | 4篇 |
药学 | 73篇 |
中国医学 | 1篇 |
肿瘤学 | 21篇 |
出版年
2021年 | 7篇 |
2018年 | 14篇 |
2016年 | 9篇 |
2015年 | 9篇 |
2014年 | 10篇 |
2013年 | 38篇 |
2012年 | 34篇 |
2011年 | 20篇 |
2010年 | 20篇 |
2009年 | 26篇 |
2008年 | 24篇 |
2007年 | 22篇 |
2006年 | 24篇 |
2005年 | 29篇 |
2004年 | 36篇 |
2003年 | 31篇 |
2002年 | 23篇 |
2001年 | 25篇 |
2000年 | 27篇 |
1999年 | 27篇 |
1998年 | 23篇 |
1997年 | 25篇 |
1996年 | 20篇 |
1995年 | 12篇 |
1994年 | 24篇 |
1993年 | 10篇 |
1992年 | 28篇 |
1991年 | 18篇 |
1990年 | 17篇 |
1989年 | 18篇 |
1988年 | 24篇 |
1987年 | 30篇 |
1986年 | 29篇 |
1985年 | 27篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 12篇 |
1981年 | 8篇 |
1979年 | 13篇 |
1978年 | 11篇 |
1977年 | 19篇 |
1976年 | 20篇 |
1975年 | 20篇 |
1974年 | 14篇 |
1973年 | 21篇 |
1971年 | 17篇 |
1970年 | 8篇 |
1969年 | 10篇 |
1968年 | 15篇 |
1967年 | 10篇 |
排序方式: 共有1049条查询结果,搜索用时 0 毫秒
101.
Dr. Shephard reviews practical advice required by the winter sportsman in relation to more fundamental aspects of the bodily response to cold. Heat loss occurs by radiation, convection, conduction, and evaporation of sweat; this loss must be made good by metabolism if the body is not to be chilled. Convection is the main source of heat loss in the sportsman, and must be minimized by appropriate clothing. Chilling below a body temperature of 95°F is undesirable; temperatures below 90°F are rapidly fatal. Heat is restored to the body by warming, by the “waste” energy of physical activity, and by shivering. 相似文献
102.
Moog R Zeiler T Heuft HG Stephan B Fischer EG Kretschmer V Rödel-Spieker R Strasser E Zingsem J 《Transfusion》2003,43(10):1502-1502
103.
104.
Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial 总被引:1,自引:0,他引:1
105.
Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody 总被引:1,自引:0,他引:1
Goodall AH; Kemble G; O'Brien DP; Rawlings E; Rotblat F; Russell GC; Janossy G; Tuddenham EG 《Blood》1982,59(3):664-670
A murine hybridoma clone is described that grows continuously in culture and produces a monoclonal antibody we have called Royal Free Monoclonal Antibody to factor IX No. 1 (RFF-IX/1). This has high affinity for a coagulation site on factor IX. RFF-IX/1 immobilised on sepharose can be used to deplete factor IX from normal human plasma. This immunoaffinity depleted plasma is indistinguishable from severe Christmas disease plasma and can be used as the substrate in a one stage coagulation assay for factor IX. The affinity column has high capacity and can be regenerated so that large scale production from normal plasma of factor IX deficient plasma as a diagnostic reagent is now feasible. 相似文献
106.
Formstone CJ; Hallam PJ; Tuddenham EG; Voke J; Layton M; Nicolaides K; Hann IM; Cooper DN 《Blood》1996,87(9):3731-3737
Molecular genetic and phenotypic analyses were performed in a highly unusual case of combined protein S and protein C deficiency manifesting in a family in which a child had died perinatally from renal vein thrombosis. Antenatal diagnosis in a second pregnancy was initially performed by indirect restriction fragment length polymorphism (RFLP) tracking using a neutral dimorphism within the PROS gene and served to exclude severe protein S deficiency. Am umbilical vein blood sample at 22 weeks gestation showed isolated protein C deficiency. This pregnancy proceeded to a full-term delivery without thrombotic complications. Molecular genetic analysis of the PROC and PROS gene segregating in the family then yielded one PROC gene lesion in the father and two PROS gene lesions, one in each parent. These lesions were shown to segregate with the respective deficiency states through the family pedigree. Analysis of DNA from paraffin-embedded liver tissue taken from the deceased child showed the presence of both PROS mutations, as well as the PROC mutation. Genotypic analysis of the second child showed a PROC mutation, but neither PROS mutation consistent with its possession of normal protein S levels and a low/borderline protein C level. Antenatal diagnosis was then performed in a third pregnancy by direct mutation detection. However, although the fetus carried only the paternal PROS and PROC gene lesions, the child developed renal thrombosis in utero. It may be that a further genetic lesion at a third locus still remains to be defined. Alternatively, the intrauterine development of thrombosis in this infant could have been caused, at least in part by a transplacental thrombotic stimulus arising in the protein S-deficient maternal circulation. This analysis may, therefore, serve as a warning against extrapolating too readily from genotype to phenotype in families with a complex thrombotic disorder. 相似文献
107.
108.
109.
Bernard Schachtel Sue Aspley Adrian Shephard Timothy Shea Gary Smith Kathleen Sanner Laurie Savino Jeanne Rezuke Emily Schachtel 《Pain》2014
A new onset-of-action model was utilized to distinguish the pharmacologic activity of flurbiprofen 8.75 mg delivered in a lozenge from the demulcent effect of the lozenge base. In a randomized, double-blind, placebo-controlled trial, patients with sore throat rated pain on a Sore Throat Pain Intensity Scale before taking one flurbiprofen or placebo lozenge and at frequent (2-minute) intervals over the first hour after treatment. Further ratings of the Sore Throat Pain Intensity Scale and other patient-reported outcomes (difficulty swallowing, swollen throat, pain relief) were obtained at varying intervals over 6 hours. Onset of pharmacologic activity was defined as the median time of first perceived pain reduction if a patient reported clinically meaningful (at least moderate) relief. The conventional method of comparing mean treatment responses at each time point was also implemented. Demulcent action was detected at the first 2-minute assessment. By the new method, 102 flurbiprofen-treated patients were identified as first perceiving pain relief at 12 minutes, compared with >120 minutes by 102 patients using placebo (P < 0.001). By the conventional method, mean percentage pain reduction for flurbiprofen 8.75 mg was first significantly differentiated from placebo at 26 minutes (P < 0.05). Efficacy of flurbiprofen lozenge was demonstrated for 3.5-4 hours on the 4 patient-reported outcomes (all P < 0.05 compared with placebo). There were no serious adverse events. This patient-centered onset-of-action model identifies the initiation of pain relief in patients who are definite drug responders, here demonstrating that a flurbiprofen 8.75-mg lozenge provides early relief of sore throat. 相似文献
110.